Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis

Authors: Shiya Ji, Xupeng Chen, Yebo Yu, Qiuping Jia, Xingxing Zhang, Zixin Gao

Source: BMC Women's Health, Vol 25, Iss 1, Pp 1-11 (2025)

Subject Terms: Network meta-analysis, Endometrial cancer, Immunotherapy, Programmed cell death protein 1, Programmed cell death ligand 1, Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/1472-6874

Access URL: https://doaj.org/article/f70456fb182343e3a76d63cf9263ade0

Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma

Authors: CAO Rui, ZENG Guineng, TIAN Yuying

Source: 陆军军医大学学报, Vol 46, Iss 24, Pp 2736-2744 (2024)

Subject Terms: oncolytic virus, reverse genetic technology, combination therapy, il-21, anti-programmed cell death protein 1 antibody, hepatocellular carcinoma, Medicine (General), R5-920

File Description: electronic resource

Relation: https://aammt.tmmu.edu.cn/html/202407051.htm; https://doaj.org/toc/2097-0927

Access URL: https://doaj.org/article/0fbabbbaae6e45d99cf2cd5817ba69b1

Pembrolizumab‐induced acquired perforating dermatosis

Authors: Yaron Gu, Dinuke deSilva, Christopher J. A. Henderson, Deshan F. Sebaratnam

Source: JEADV Clinical Practice, Vol 3, Iss 5, Pp 1611-1614 (2024)

Subject Terms: drug eruptions, immune checkpoint inhibitors, PD‐1 inhibitors, programmed cell death protein 1 inhibitor, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://doaj.org/toc/2768-6566

Access URL: https://doaj.org/article/3cde5fcb94764132b3681a89de1d4f66

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy(HAIC) Combined with PD-1 Inhibitors for Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Multicenter Propensity Score Matching Analysis

Authors: Zhang F, Zhong S, Wei Q, Zhang H, Hu H, Zeng B, Zheng X

Source: Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1961-1978 (2024)

Subject Terms: hepatocellular carcinoma, programmed cell death protein 1, hepatic artery infusion chemotherapy, macrovascular···invasion, propensity score matching., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/efficacy-and-safety-of-hepatic-arterial-infusion-chemotherapyhaic-comb-peer-reviewed-fulltext-article-JHC; https://doaj.org/toc/2253-5969

Access URL: https://doaj.org/article/b21313dcd51546379e073df1053e484a

High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis

Authors: Ting Sun, Yi Yang, Yiwen Qiu, Tao Wang, Ming Yang, Shu Shen, Wentao Wang

Source: Parasites & Vectors, Vol 17, Iss 1, Pp 1-12 (2024)

Subject Terms: Alveolar echinococcosis, Echinococcus multilocularis, Programmed cell death protein 1, Cytotoxic T lymphocyte-associated antigen 4, Immune suppression, Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: https://doaj.org/toc/1756-3305

Access URL: https://doaj.org/article/132b5309919b4b5db3746b728d035400

Resveratrol alleviates testicular toxicity induced by anti-PD-1 through regulating the NRF2-SLC7A11-GPX4 pathway

Authors: Halahati· Tuerxun, Yixin Zhao, Yawen Li, Xingyu Liu, Shuhui Wen, Yuguang Zhao

Source: Frontiers in Immunology, Vol 16 (2025)

Subject Terms: immune checkpoint inhibitors, anti-programmed cell death protein 1, reproductive toxicity, oxidative stress, ferroptosis, resveratrol, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1529991/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/0e8328f999124bfab289c0a853c5c9f5

Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

Authors: Wanming He, Lihua Tong, Yanling Yuan, Xia Yang, Wen Yang, Xingxi Pan

Source: Frontiers in Pharmacology, Vol 16 (2025)

Subject Terms: anti-vascular endothelial growth factor, immune checkpoint inhibitor, programmed cell death protein 1, adverse events, hepatocellular carcinoma, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1448095/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/3dd29ead2aba4a79a32264b47b82622d

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

Authors: Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang

Source: Frontiers in Immunology, Vol 16 (2025)

Subject Terms: PD-1 inhibitor, programmed cell death protein 1 inhibitor, CTLA-4 inhibitor, non-small cell lung cancer, overall survival, objective response rate, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515027/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/20b569c9595247aa9409947a8b2c68e6

The comparison of perioperative outcomes and disease-free survival between pneumonectomy after immunochemotherapy and after isolated chemotherapy: one single center experience

Authors: Guodong Zhang, Yongle Zhu, Zhigang Shi, Zhendan Wang, Pingping Song

Source: Journal of Cardiothoracic Surgery, Vol 19, Iss 1, Pp 1-7 (2024)

Subject Terms: Programmed cell death protein 1 inhibitors, Chemotherapy, Pneumonectomy, Disease-free survival, Surgery, RD1-811, Anesthesiology, RD78.3-87.3

File Description: electronic resource

Relation: https://doaj.org/toc/1749-8090

Access URL: https://doaj.org/article/0388bef6ceb74ba1ab6846d344a65805

Genetic polymorphism and immunological evaluation of PD-1 in Iraqi patients with acute myeloid leukemia

Authors: Aseel S. Mahmood

Source: Journal of Advanced Pharmaceutical Technology & Research, Vol 15, Iss 3, Pp 225-230 (2024)

Subject Terms: acute myeloid leukemia, gene polymorphism, programmed cell death protein 1 gene, snp, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://journals.lww.com/10.4103/JAPTR.JAPTR_107_24; https://doaj.org/toc/2231-4040; https://doaj.org/toc/0976-2094

Access URL: https://doaj.org/article/fdd156cf97a44b60946369b2bfa22eeb

Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody

Authors: Lin, Jinguan ^a, Qu, Song ^b, Yang, Kunyu ^c, Zhang, Tao ^d, Bai, Yuansong ^e, Wu, Jian ^f, Huang, Yanjing ^g, Fang, Meiyu ^h, Liu, Xianling ⁱ, Huang, Xiaoming ^j, Chen, Nianyong ^k, Li, Zhendong ^l, Li, Weidong ^m, Zhang, Songnan ⁿ, Zhang, Shurong ^o, Hu, Guangyuan ^p, Sun, Yan ^q, Chen, Xiaohong ^o, Liu, Yanyan ^r, Jing, Shanghua ^s, Shen, Liangfang ^t, Chang, Zhiwei ^u, Xie, Liangzhi ^v, Gai, Wenlin ^v, Zhou, Qiang ^v, Chen, Xinyue ^v, Yi, Jiang ^v, Guo, Ye ^{w, ⁎}

Source: In Cancer Letters 31 March 2025 613

Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications

Authors: Piao, Mingjian ^{a, 1}, Zhang, Nan ^{a, 1}, Li, Jiongyuan ^{a, 1}, Li, Chengjie ^{a, 1}, Xun, Ziyu ^a, Zhang, Longhao ^a, Wang, Shanshan ^a, Sun, Boyu ^a, Li, Shuofeng ^a, Yang, Xu ^b, Yang, Xiaobo ^{a, ⁎⁎⁎}, Wang, Hanping ^{c, ⁎⁎}, Zhao, Haitao ^{a, ⁎}

Source: In International Immunopharmacology 6 February 2025 147

Gastric cancer mesenchymal stem cells upregulate PD-1 expression on the CD8+ T cells by regulating the PI3K/AKT pathway

Authors: Ji, Weimeng ^{a, b, c}, Xu, Juan ^e, Huang, Chao ^c, Liu, Ting ^c, Chen, Shihan ^c, Zhao, Yuanyuan ^c, Zhou, Chenglin ^e, Sun, Li ^d, Wang, Mei ^c, Wang, Deqiang ^{a, b, ⁎}, Zhu, Wei ^{a, b, c, ⁎}

Source: In Molecular Immunology February 2025 178:97-106

Radiotherapy combined with first-line anti-programmed cell death protein 1 immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study

Authors: Huang, Yu ^{a, b, c, 1}, Ding, Peng ^{a, b, c, 1}, Zhang, Ruiguang ^{a, b, c, 1}, Zhang, Yongchang ^d, Tong, Fan ^{a, b, c}, Cheng, Shishi ^{a, b, c}, Peng, Ling ^{a, b, c}, Jie, Xiaohua ^{a, b, c}, Wang, Jian ^{a, b, c}, Liu, Pian ^{a, b, c}, Zhang, Sheng ^{a, b, c}, Wu, Gang ^{a, b, c}, Yang, Nong ^{e, ⁎}, Dong, Xiaorong ^{a, b, c, ⁎⁎}

Source: In Cancer Pathogenesis and Therapy February 2025

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

Authors: Lindberg, Amanda ^a, Muhl, Lars ^{b, c}, Yu, Hui ^a, Hellberg, Louise ^a, Artursson, Rebecca ^a, Friedrich, Jakob ^a, Backman, Max ^a, Hekmati, Neda ^a, Mattsson, Johanna ^a, Lindskog, Cecilia ^a, Brunnström, Hans ^d, Botling, Johan ^{a, e}, Mezheyeuski, Artur ^{f, g}, Broström, Erika ^{a, h}, Gulyas, Miklos ^a, Kärre, Klas ⁱ, Isaksson, Johan ^a, Micke, Patrick ^a, Strell, Carina ^{a, c, ∗}

Source: In Journal of Thoracic Oncology December 2024

The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation

Authors: Yalei Hu, Yuxin Wang, Kaili Min, Huisheng Zhou, Xiaoning Gao

Source: Frontiers in Immunology, Vol 15 (2024)

Subject Terms: immune checkpoint inhibitors, programmed cell death protein 1, programmed cell death 1 ligand 1, allogeneic hematopoietic cell transplant, graft-versus-host disease, immune-related adverse events, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1491330/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/b4f2038ecc8a4f0d8e24351ec1c56238

The potential role of PD-1/PD-L1 small molecule inhibitors in colorectal cancer with different mechanisms of action

Authors: Kuno, Suhaibee, Pakpian, Nattaporn, Muanprasat, Chatchai ^⁎

Source: In European Journal of Pharmacology 5 April 2025 992

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study

Authors: Jian Zhang, Aiqin Gao, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Yuping Sun

Source: Respiratory Research, Vol 25, Iss 1, Pp 1-8 (2024)

Subject Terms: Extensive-stage small cell lung cancer (ES-SCLC), Immunotherapy, Programmed cell death protein 1 (PD-1), Programmed cell death ligand protein 1 (PD-L1), Immune-related adverse events (irAEs), Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/1465-993X

Access URL: https://doaj.org/article/81edf98278c9466d9563b891d6a4d6fb

Pembrolizumab associated hypereosinophilia in locally advanced triple-negative breast cancer

Authors: Remo Poto, Antonio di Salvatore, Laura Stigliano, Elisabetta Simeone, Maria Teresa Narducci, Michela Williams, Alessandra Cuomo, Carlo Gabriele Tocchetti, Amato de Paulis, Gilda Varricchi

Source: Exploration of Medicine, Vol 6, p 1001294 (2025)

Subject Terms: breast cancer, hypereosinophilia, immune-checkpoint inhibitors, pembrolizumab, programmed cell death protein 1 (pd-1), Other systems of medicine, RZ201-999

File Description: electronic resource

Relation: https://www.explorationpub.com/uploads/Article/A1001294/1001294.pdf; https://doaj.org/toc/2692-3106

Access URL: https://doaj.org/article/0d2778a38591426c8e3c5fab736cf83c

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Authors: Long, G.V. ^{1, 2, 3, 4, ∗}, Carlino, M.S. ^{1, 2, 5}, McNeil, C. ⁶, Ribas, A. ⁷, Gaudy-Marqueste, C. ⁸, Schachter, J. ⁹, Nyakas, M. ¹⁰, Kee, D. ¹¹, Petrella, T.M. ¹², Blaustein, A. ¹³, Lotem, M. ¹⁴, Arance, A.M. ¹⁵, Daud, A.I. ¹⁶, Hamid, O. ¹⁷, Larkin, J. ¹⁸, Yao, L. ¹⁹, Singh, R. ¹⁹, Lal, R. ¹⁹, Robert, C. ^{20, ∗}

Source: In Annals of Oncology December 2024 35(12):1191-1199